Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care
Authors:
- Fred SaadFSFred Saad
- Carl OlssonCOCarl Olsson
- Claude C. SchulmanCSClaude C. Schulman
- 1 December 2004
- journal article
- review article
- Published by Elsevier in European Urology
- Vol. 46 (6) , 731-740
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Bone loss and the evolving role of bisphosphonate therapy in prostate cancerUrologic Oncology: Seminars and Original Investigations, 2003
- How are we looking after prostate cancer?QJM: An International Journal of Medicine, 2003
- Osteoporosis during androgen deprivation therapy for prostate cancerUrology, 2002
- The Influence of Osteoporotic Fractures on Health-Related Quality of Life in Community-Dwelling Men and Women across CanadaOsteoporosis International, 2001
- Mortality, Morbidity, and Assessment of Fracture Risk in Male OsteoporosisCalcified Tissue International, 2001
- Low bone mineral density in hormone-na ve men with prostate carcinomaCancer, 2001
- Biochemical markers and skeletal metastasesCancer, 2000
- TREATMENT OF VITAMIN D DEFICIENCY IN PATIENTS WITH METASTATIC PROSTATE CANCER MAY IMPROVE BONE PAIN AND MUSCLE STRENGTHJournal of Urology, 2000
- Age-related hip fractures in men: Clinical spectrum and short-term outcomesOsteoporosis International, 1995
- Quality-of-life outcomes in men treated for localized prostate cancerJAMA, 1995